Home chemotherapy for acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether giving a chemotherapy drug called cytarabine at home is safe and practical for patients with acute myeloid leukemia (AML), a type of blood cancer. It also looks at costs and how well it works in practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with acute myeloid leukemia (AML)
- You are able to give informed consent
- You can read, write, and speak Danish or English
- You have no severe mental disability that would make participation unethical
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding natural killer (NK) cell infusions to standard consolidation chemotherapy helps keep acute myeloid leukemia (AML) in remission. It's for people with AML who are already in remission after their first treatment.
This Phase 3 trial compares two chemotherapy approaches given first (induction) for people newly diagnosed with AML. It aims to find which option works better and is safer to help achieve remission.
This trial aims to help doctors choose the best treatment for older adults with acute myeloid leukemia (AML) by using a special health assessment that looks at your overall well-being. The study will compare different treatment options based on this assessment, with the goal of improving outcomes and quality of life.
This non-interventional study follows adults with acute myeloid leukemia (AML) to better understand the disease and how patients do in real-world care. It may help researchers compare outcomes across different types of AML, but you would not receive a study treatment just for joining.
This trial compares three chemotherapy combinations (HVA vs IA/DA or VA) for people with newly diagnosed high-risk acute myeloid leukemia (AML). It aims to find which treatment works better.
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Hear when a new Hematologic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.